Valuation: Rein Therapeutics Inc.

Market Cap 30.65M 27.95M 25.85M 23.32M 43.93M 2.86B 45.66M 312M 123M 1.55B 115M 113M 4.88B P/E 2026 *
-0.87x
P/E 2027 * -0.78x
Enterprise Value 30.65M 27.95M 25.85M 23.32M 43.93M 2.86B 45.66M 312M 123M 1.55B 115M 113M 4.88B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
94.93%
Yield 2026 *
-
Yield 2027 * -
1 day+3.01%
1 week-35.71%
Current month-46.27%
1 month-34.78%
3 months-54.55%
6 months-63.82%
Current year-68.97%
1 week 0.28
Extreme 0.2844
0.57
1 month 0.28
Extreme 0.2844
0.75
Current year 0.28
Extreme 0.2844
2.1
1 year 0.28
Extreme 0.2844
2.1
3 years 0.28
Extreme 0.2844
7.42
5 years 0.28
Extreme 0.2844
15
10 years 0.28
Extreme 0.2844
309.6
Manager TitleAgeSince
Chief Executive Officer 60 11/03/2024
Director of Finance/CFO 64 16/05/2024
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 70 01/06/2013
Chairman 71 31/10/2023
Director/Board Member 60 11/03/2024
Date Insider Type Main position Quantity % Market Cap. Importance
27/05/26 Buy

Chairman

4,500 0.0058%
08/05/26 Free

Chief Executive Officer

-150,000 0.1922%
14/11/25
Voss Capital LP
BuyCompany 104,183 0.4424%
Change 5-day change 1-year change 3-year change Capi.($)
+3.01%-35.71%-71.43%-80.95% 30.65M
+0.19%-2.90%+56.40%+69.15% 65.45B
+0.28%-2.82%+8.05%+91.17% 58.93B
+0.48%+0.54%+26.44%+87.46% 55.21B
+0.28%-3.53%+13.42%+113.59% 46.1B
+0.23%-5.05%+18.36%+25.39% 42.49B
+3.61%+3.86%+22.82%+46.39% 35.56B
+3.86%-7.06%+132.38%+654.23% 34.57B
+1.40%-0.25%+77.92%+58.60% 32.46B
+17.17%+2.98%-40.27%+393.87% 26.28B
Average +3.10%-6.62%+24.41%+145.89% 40B
Weighted average by Cap. +2.15%-2.57%+34.96%+144.95%

Financials

2026 *2027 *
Net sales - -
Net income -28.3M -25.81M -23.86M -21.54M -40.56M -2.64B -42.16M -288M -114M -1.43B -106M -104M -4.51B -36.36M -33.16M -30.66M -27.67M -52.12M -3.4B -54.17M -370M -146M -1.83B -136M -134M -5.79B
Net Debt - -
Projected Income Statement - Annual - Rein Therapeutics Inc.
Logo Rein Therapeutics Inc.
Rein Therapeutics, Inc., formerly Aileron Therapeutics, Inc., is a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class therapies to address significant unmet medical needs in orphan pulmonary and fibrosis indications. The Company's lead product candidate, LTI-03 (idiopathic pulmonary fibrosis), is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. Its second product candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusions. LTI-01 has received Orphan Drug Designation in the United States and European Union and Fast Track Designation in the United States. Its pipeline also includes LTI-05 (cystic fibrosis).
Employees
10
Date Price Change Volume
19/11/26 $0.3600 +1.32% 19,863
18/11/26 $0.3553 -0.31% 815,803
17/11/26 $0.3564 -10.90% 2,484,299
16/11/26 $0.4000 -27.55% 8,481,447
13/11/26 $0.5521 -1.41% 488,672
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Rein Therapeutics Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.3553USD
Average target price
6.000USD
Spread / Average Target
+1,588.71%
  1. Stock Market
  2. Stocks
  3. RNTX Stock